Targeting immune checkpoints in hematological malignancies

by Basit Salik, Mark J. Smyth, Kyohei Nakamura
Published 2020-08-01

Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity

by William C. Dougall, Amelia Roman Aguilera, Mark J. Smyth
Published 2019-01-01

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

by Jake S. O’Donnell, Mark J. Smyth, Michele W. L. Teng
Published 2016-10-01

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

by Jing Liu, Jake S. O’Donnell, Juming Yan, Jason Madore, Stacey Allen, Mark J. Smyth, Michele W. L. Teng
Published 2019-05-01

The role of NK cells and CD39 in the immunological control of tumor metastases

by Haiyan Zhang, Dipti Vijayan, Xian-Yang Li, Simon C. Robson, Nishamol Geetha, Michele W. L. Teng, Mark J. Smyth
Published 2019-06-01

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

by Elizabeth Ahern, Heidi Harjunpää, Jake S. O'Donnell, Stacey Allen, William C. Dougall, Michele W. L. Teng, Mark J. Smyth
Published 2018-06-01

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer

by Alexander Liede, Rohini K. Hernandez, Sally W. Wade, Ronghai Bo, Nathan C. Nussbaum, Elizabeth Ahern, William C. Dougall, Mark J. Smyth
Published 2018-12-01

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

by Kazuyoshi Takeda, Masafumi Nakayama, Yoshihiro Hayakawa, Yuko Kojima, Hiroaki Ikeda, Naoko Imai, Kouetsu Ogasawara, Ko Okumura, David M. Thomas, Mark J. Smyth
Published 2017-02-01

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

by Jing Liu, Elisa A. Rozeman, Jake S. O’Donnell, Stacey Allen, Lorenzo Fanchi, Mark J. Smyth, Christian U. Blank, Michele W.L. Teng
Published 2019-02-01

Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy

by Deepak Mittal, Dipti Vijayan, Joost Neijssen, Joost Kreijtz, Maurice M. J. M. Habraken, Hans Van Eenennaam, Andrea Van Elsas, Mark J. Smyth
Published 2019-11-01

Physicochemical properties that control protein aggregation also determine whether a protein is retained or released from necrotic cells

by Andre L. Samson, Bosco Ho, Amanda E. Au, Simone M. Schoenwaelder, Mark J. Smyth, Stephen P. Bottomley, Oded Kleifeld, Robert L. Medcalf
Published 2016-01-01

Plasmodium strain determines dendritic cell function essential for survival from malaria.

by Michelle N Wykes, Xue Q Liu, Lynette Beattie, Danielle I Stanisic, Katryn J Stacey, Mark J Smyth, Ranjeny Thomas, Michael F Good
Published 2007-07-01

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

by Dipti Vijayan, Deborah S. Barkauskas, Kimberley Stannard, Erin Sult, Rebecca Buonpane, Kazuyoshi Takeda, Michele W. L. Teng, Kris Sachsenmeier, Carl Hay, Mark J. Smyth
Published 2017-05-01

Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients

by Vijayendra Dasari, Andrea Schuessler, Corey Smith, Yide Wong, John J Miles, Mark J Smyth, George Ambalathingal, Ross Francis, Scott Campbell, Daniel Chambers, Rajiv Khanna
Published 2016-01-01

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

by Eva M. Putz, Camille Guillerey, Kevin Kos, Kimberley Stannard, Kim Miles, Rebecca B. Delconte, Kazuyoshi Takeda, Sandra E. Nicholson, Nicholas D. Huntington, Mark J. Smyth
Published 2017-02-01

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multi...

by Elizabeth Ahern, Annette Cubitt, Emma Ballard, Michele W. L. Teng, William C. Dougall, Mark J. Smyth, David Godbolt, Rishendran Naidoo, Amanda Goldrick, Brett G. M. Hughes
Published 2019-12-01

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity

by Amelia Roman Aguilera, Viviana P. Lutzky, Deepak Mittal, Xian-Yang Li, Kimberley Stannard, Kazuyoshi Takeda, Günter Bernhardt, Michele W. L. Teng, William C. Dougall, Mark J. Smyth
Published 2018-05-01

Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis.

by Amanda C Stanley, Yonghong Zhou, Fiona H Amante, Louise M Randall, Ashraful Haque, Daniel G Pellicci, Geoff R Hill, Mark J Smyth, Dale I Godfrey, Christian R Engwerda
Published 2008-02-01

DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation

by Ludovic Martinet, Lucas Ferrari De Andrade, Camille Guillerey, Jason S. Lee, Jing Liu, Fernando Souza-Fonseca-Guimaraes, Dana S. Hutchinson, Tatiana B. Kolesnik, Sandra E. Nicholson, Nicholas D. Huntington, Mark J. Smyth
Published 2015-04-01

Correction to: YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma

by Jiajie Hou, He Zhang, Jun Liu, Zhenjun Zhao, Jianye Wang, Zhike Lu, Bian Hu, Jiankui Zhou, Zhicong Zhao, Mingxuan Feng, Haiyan Zhang, Bin Shen, Xingxu Huang, Beicheng Sun, Mark J. Smyth, Chuan He, Qiang Xia
Published 2020-09-01